Oxford University researchers have made a significant step towards realizing a form of ‘biological electricity’ that could be used in a variety of bioengineering and biomedical applications, including communication with living human cells.
ConSynance wins FDA designation for Prader-Willi syndrome therapy – Pharmaceutical Technology
CSTI-500 works by increasing the levels of monoamine neurotransmitters in the synaptic cleft. Image credit: Shutterstock / nobeastsofierce. The US Food and Drug Administration (FDA)
July 25, 2024